Evidence map›Paper›PMID 27869812›Full record

ArticleBone marrow transplantation2017

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation.

F He, M R Verneris, S Cooley, B R Blazar, M L MacMillan, L F Newell, A Panoskaltsis-Mortari, T DeFor, D J Weisdorf, S G Holtan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

F HeBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
M R VernerisBlood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
S CooleyBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
B R BlazarBlood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
M L MacMillanBlood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
L F NewellCenter for Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA.
A Panoskaltsis-MortariBlood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
T DeForBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
D J WeisdorfBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
S G HoltanBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USOregon Health & Science University · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI John E. Wagner · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Scholars in Women's Health Research Across the LifespanK12HD043488 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MYATT, LESLIE · 2002 to 2023
$10.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA077598NIAID NIH HHS R37 AI034495NICHD NIH HHS K12 HD043488
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationAcute DiseaseAdultAllograftsEpidermal Growth FactorFemaleGraft vs Host DiseaseHumansMaleNeoplasm ProteinsTime FactorsEpidermal Growth FactorNeoplasm Proteins

Identifiers

PMID27869812
PMCPMC5582052
OpenAlexW2554958927

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.